Titre : Tospovirus

Tospovirus : Questions médicales fréquentes

Termes MeSH sélectionnés :

Probability
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Tospovirus : Questions médicales les plus fréquentes", "headline": "Tospovirus : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Tospovirus : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-02", "dateModified": "2025-02-25", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Tospovirus" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Bunyaviridae", "url": "https://questionsmedicales.fr/mesh/D002043", "about": { "@type": "MedicalCondition", "name": "Bunyaviridae", "code": { "@type": "MedicalCode", "code": "D002043", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B04.820.480.750" } } }, "about": { "@type": "MedicalCondition", "name": "Tospovirus", "alternateName": "Tospovirus", "code": { "@type": "MedicalCode", "code": "D017865", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Xiaorong Tao", "url": "https://questionsmedicales.fr/author/Xiaorong%20Tao", "affiliation": { "@type": "Organization", "name": "Department of Plant Pathology, Nanjing Agricultural University, Nanjing 210095, China; email: taoxiaorong@njau.edu.cn." } }, { "@type": "Person", "name": "Min Zhu", "url": "https://questionsmedicales.fr/author/Min%20Zhu", "affiliation": { "@type": "Organization", "name": "Department of Plant Pathology, Nanjing Agricultural University, Nanjing 210095, China; email: taoxiaorong@njau.edu.cn." } }, { "@type": "Person", "name": "Anna E Whitfield", "url": "https://questionsmedicales.fr/author/Anna%20E%20Whitfield", "affiliation": { "@type": "Organization", "name": "Department of Entomology and Plant Pathology, North Carolina State University, Raleigh, NC 27695, USA." } }, { "@type": "Person", "name": "Dorith Rotenberg", "url": "https://questionsmedicales.fr/author/Dorith%20Rotenberg", "affiliation": { "@type": "Organization", "name": "Department of Entomology and Plant Pathology, North Carolina State University, Raleigh, NC 27695, USA. Electronic address: drotenb@ncsu.edu." } }, { "@type": "Person", "name": "Richard Kormelink", "url": "https://questionsmedicales.fr/author/Richard%20Kormelink", "affiliation": { "@type": "Organization", "name": "Laboratory of Virology, Department of Plant Sciences, Wageningen University, 6708PB Wageningen, The Netherlands." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance.", "datePublished": "2023-03-04", "url": "https://questionsmedicales.fr/article/36880088", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1093/jacamr/dlad011" } }, { "@type": "ScholarlyArticle", "name": "Serum multi-cytokines screening identifies TRAIL and IL-10 as probable new biomarkers for prostate health index diagnostic utility adjustment in grey zone aggressive prostate cancer detection: A single-center data in China.", "datePublished": "2022-08-18", "url": "https://questionsmedicales.fr/article/36059480", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2022.901176" } }, { "@type": "ScholarlyArticle", "name": "Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.", "datePublished": "2022-09-09", "url": "https://questionsmedicales.fr/article/36088952", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/S2352-4642(22)00245-0" } }, { "@type": "ScholarlyArticle", "name": "'I probably wouldn't want to talk about anything too personal': A qualitative exploration of how issues of privacy, confidentiality and surveillance in the home impact on access and engagement with online services and spaces for care-experienced young people.", "datePublished": "2023-10-19", "url": "https://questionsmedicales.fr/article/37873026", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/03085759231203019" } }, { "@type": "ScholarlyArticle", "name": "Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis.", "datePublished": "2022-08-27", "url": "https://questionsmedicales.fr/article/36145549", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/pharmaceutics14091801" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Virus", "item": "https://questionsmedicales.fr/mesh/D014780" }, { "@type": "ListItem", "position": 3, "name": "Virus à ARN", "item": "https://questionsmedicales.fr/mesh/D012328" }, { "@type": "ListItem", "position": 4, "name": "Virus à ARN de polarité négative", "item": "https://questionsmedicales.fr/mesh/D000086103" }, { "@type": "ListItem", "position": 5, "name": "Bunyaviridae", "item": "https://questionsmedicales.fr/mesh/D002043" }, { "@type": "ListItem", "position": 6, "name": "Tospovirus", "item": "https://questionsmedicales.fr/mesh/D017865" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Tospovirus - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Tospovirus", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-12", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Tospovirus", "description": "Comment diagnostiquer une infection par Tospovirus ?\nQuels tests sont utilisés pour identifier Tospovirus ?\nLes symptômes peuvent-ils aider au diagnostic ?\nPeut-on diagnostiquer Tospovirus par culture cellulaire ?\nLes tests rapides existent-ils pour Tospovirus ?", "url": "https://questionsmedicales.fr/mesh/D017865?mesh_terms=Probability&page=275#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Tospovirus", "description": "Quels sont les symptômes typiques des plantes infectées ?\nLes symptômes varient selon les espèces de plantes ?\nLes fruits peuvent-ils montrer des symptômes ?\nLes symptômes sont-ils visibles dès l'infection ?\nLes symptômes sont-ils réversibles ?", "url": "https://questionsmedicales.fr/mesh/D017865?mesh_terms=Probability&page=275#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Tospovirus", "description": "Comment prévenir l'infection par Tospovirus ?\nLes rotations de cultures aident-elles ?\nLes serres peuvent-elles prévenir l'infection ?\nFaut-il désinfecter les outils de jardinage ?\nLes barrières physiques sont-elles efficaces ?", "url": "https://questionsmedicales.fr/mesh/D017865?mesh_terms=Probability&page=275#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Tospovirus", "description": "Quels traitements existent pour les plantes infectées ?\nPeut-on utiliser des pesticides contre Tospovirus ?\nLa résistance des plantes est-elle une option ?\nLes traitements biologiques sont-ils efficaces ?\nComment gérer une épidémie de Tospovirus ?", "url": "https://questionsmedicales.fr/mesh/D017865?mesh_terms=Probability&page=275#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Tospovirus", "description": "Quelles sont les complications d'une infection par Tospovirus ?\nLes infections peuvent-elles affecter d'autres cultures ?\nLes plantes infectées peuvent-elles devenir des réservoirs ?\nLes infections chroniques sont-elles possibles ?\nLes Tospovirus peuvent-ils affecter la santé humaine ?", "url": "https://questionsmedicales.fr/mesh/D017865?mesh_terms=Probability&page=275#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Tospovirus", "description": "Quels sont les principaux facteurs de risque d'infection ?\nLes pratiques agricoles influencent-elles le risque ?\nLes conditions climatiques jouent-elles un rôle ?\nLes variétés de plantes affectent-elles le risque ?\nLes zones urbaines sont-elles à risque ?", "url": "https://questionsmedicales.fr/mesh/D017865?mesh_terms=Probability&page=275#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection par Tospovirus ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par PCR, ELISA ou observation des symptômes sur les plantes." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour identifier Tospovirus ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests sérologiques et moléculaires comme la PCR sont couramment utilisés." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils aider au diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes comme le flétrissement et les taches foliaires sont indicatifs." } }, { "@type": "Question", "name": "Peut-on diagnostiquer Tospovirus par culture cellulaire ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "La culture cellulaire n'est pas efficace pour Tospovirus, car ils infectent principalement les plantes." } }, { "@type": "Question", "name": "Les tests rapides existent-ils pour Tospovirus ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests rapides basés sur l'ELISA sont disponibles pour une détection précoce." } }, { "@type": "Question", "name": "Quels sont les symptômes typiques des plantes infectées ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent flétrissement, décoloration, et taches sur les feuilles." } }, { "@type": "Question", "name": "Les symptômes varient selon les espèces de plantes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier selon l'espèce de plante infectée par Tospovirus." } }, { "@type": "Question", "name": "Les fruits peuvent-ils montrer des symptômes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les fruits peuvent présenter des déformations et des taches en cas d'infection." } }, { "@type": "Question", "name": "Les symptômes sont-ils visibles dès l'infection ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Non, les symptômes peuvent prendre plusieurs jours à semaines pour apparaître." } }, { "@type": "Question", "name": "Les symptômes sont-ils réversibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Non, une fois que les symptômes apparaissent, la plante ne peut pas guérir complètement." } }, { "@type": "Question", "name": "Comment prévenir l'infection par Tospovirus ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut l'utilisation de semences saines et la gestion des insectes vecteurs." } }, { "@type": "Question", "name": "Les rotations de cultures aident-elles ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la rotation des cultures peut réduire la propagation des Tospovirus." } }, { "@type": "Question", "name": "Les serres peuvent-elles prévenir l'infection ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les serres protègent les plantes des insectes vecteurs et des infections virales." } }, { "@type": "Question", "name": "Faut-il désinfecter les outils de jardinage ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, désinfecter les outils aide à prévenir la transmission des virus entre les plantes." } }, { "@type": "Question", "name": "Les barrières physiques sont-elles efficaces ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les filets anti-insectes peuvent réduire l'exposition aux vecteurs de Tospovirus." } }, { "@type": "Question", "name": "Quels traitements existent pour les plantes infectées ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de traitement antiviral spécifique, la gestion des symptômes est essentielle." } }, { "@type": "Question", "name": "Peut-on utiliser des pesticides contre Tospovirus ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les pesticides ne traitent pas le virus, mais peuvent contrôler les insectes vecteurs." } }, { "@type": "Question", "name": "La résistance des plantes est-elle une option ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines variétés de plantes sont génétiquement résistantes aux Tospovirus." } }, { "@type": "Question", "name": "Les traitements biologiques sont-ils efficaces ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements biologiques peuvent aider à réduire les symptômes, mais ne guérissent pas." } }, { "@type": "Question", "name": "Comment gérer une épidémie de Tospovirus ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Il est crucial d'éliminer les plantes infectées et de contrôler les vecteurs comme les thrips." } }, { "@type": "Question", "name": "Quelles sont les complications d'une infection par Tospovirus ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la réduction des rendements et la dégradation de la qualité des cultures." } }, { "@type": "Question", "name": "Les infections peuvent-elles affecter d'autres cultures ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une infection peut se propager à d'autres cultures par des vecteurs comme les thrips." } }, { "@type": "Question", "name": "Les plantes infectées peuvent-elles devenir des réservoirs ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les plantes infectées peuvent servir de réservoirs pour la propagation du virus." } }, { "@type": "Question", "name": "Les infections chroniques sont-elles possibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines plantes peuvent devenir des porteuses chroniques de Tospovirus sans symptômes." } }, { "@type": "Question", "name": "Les Tospovirus peuvent-ils affecter la santé humaine ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Non, les Tospovirus n'infectent pas les humains, mais ils impactent l'agriculture." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque d'infection ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent la présence de vecteurs comme les thrips et des conditions climatiques favorables." } }, { "@type": "Question", "name": "Les pratiques agricoles influencent-elles le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des pratiques comme la monoculture augmentent le risque d'infection par Tospovirus." } }, { "@type": "Question", "name": "Les conditions climatiques jouent-elles un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des conditions chaudes et humides favorisent la propagation des Tospovirus." } }, { "@type": "Question", "name": "Les variétés de plantes affectent-elles le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines variétés sont plus sensibles aux infections par Tospovirus que d'autres." } }, { "@type": "Question", "name": "Les zones urbaines sont-elles à risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les zones urbaines peuvent être à risque en raison de la proximité des cultures et des vecteurs." } } ] } ] }

Sources (2748 au total)

Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance.

To assess the relationship between renal function and efficacy/safety of imipenem/cilastatin/relebactam for the treatment of hospital-acquired/ventilator-associated pneumonia (HABP/VABP) from RESTORE-... Adults with HABP/VABP were randomized 1:1 to IV imipenem/cilastatin/relebactam 1.25 g or piperacillin/tazobactam 4.5 g every 6 h for 7-14 days. Initial doses were selected by CL... The modified ITT population comprised those with normal renal function (... Prescribing information-defined dose adjustments in participants with baseline RI and full dosing of imipenem/cilastatin/relebactam 1.25 g every 6 h for participants with normal renal function or augm...

Serum multi-cytokines screening identifies TRAIL and IL-10 as probable new biomarkers for prostate health index diagnostic utility adjustment in grey zone aggressive prostate cancer detection: A single-center data in China.

To identify less invasive and easily applicable serum cytokine-derived biomarkers which contribute to the diagnostic utility and risk assessment ability of the prostate health index (PHI) based multiv... Serum 45 cytokines screening was performed in a small training cohort consisting of 10 sera by Luminex liquid array-based multiplexed immunoassays and identified TRAIL and IL-10 as new biomarkers for ... TRAIL and IL-10 were identified as potential serum biomarkers for AG PCa detection by the result of multi-cytokines screening in the univariate analysis, while multivariable logistic regression confir... We suggest a significant advantage for the PHI-based multivariate combinations of serum TRAIL and IL-10 comparing to PHI or other serum-derived biomarkers alone in the detection and risk stratificatio...

Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.

Switching from intravenous antibiotic therapy to oral antibiotic therapy among neonates is not yet practised in high-income settings due to uncertainties about exposure and safety. We aimed to assess ... In this multicentre, randomised, open-label, non-inferiority trial, patients were recruited at 17 hospitals in the Netherlands. Neonates (postmenstrual age ≥35 weeks, postnatal age 0-28 days, bodyweig... Between Feb 8, 2018 and May 12, 2021, 510 neonates were randomly assigned (n=255 oral amoxicillin-clavulanic group; n=255 intravenous antibiotic group). After excluding those who withdrew consent (n=4... An early intravenous-to-oral antibiotic switch with amoxicillin-clavulanic acid is non-inferior to a full course of intravenous antibiotics in neonates with probable bacterial infection and is not ass... The Netherlands Organization for Health Research and Development, Innovatiefonds Zorgverzekeraars, and the Sophia Foundation for Scientific Research....

'I probably wouldn't want to talk about anything too personal': A qualitative exploration of how issues of privacy, confidentiality and surveillance in the home impact on access and engagement with online services and spaces for care-experienced young people.

This paper draws on a qualitative interview-based study that explored online mental health and wellbeing interventions and services for care-experienced young people. The study involved young people (...

Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047).

The risk and survival of patients with non-small cell lung cancer (NSCLC) with pre-existing autoimmune disorders (AIDs) receiving immune checkpoint blockade (ICB) therapy have not been clearly establi... This multi-institutional, retrospective cohort study was conducted in collaboration with 20 centers in Japan.... In total, 229 patients with advanced or recurrent NSCLC and pre-existing AID, with or without ICB treatment from January 2010-February 2020, were included and analyzed. Among 69 patients who received ... These findings revealed a novel risk factor for AID flares following ICB treatment, that is the diagnosis of NSCLC within 1 year of AID diagnosis, and showed that ICBs may improve survival in this pop...

Mandibular dose-volume predicts time-to-osteoradionecrosis in an actuarial normal-tissue complication probability (NTCP) model: External validation of right-censored clinico-dosimetric and competing risk application across international multi-institutional observational cohorts and online graphical user interface clinical support tool assessment.

Existing studies on osteoradionecrosis of the jaw (ORNJ) have primarily used cross-sectional data, assessing risk factors at a single time point. Determining the time-to-event profile of ORNJ has impo... Demographic, clinical and dosimetric data were retrospectively obtained for a clinical observational cohort of 1129 patients with HNC treated with radiotherapy (RT) at The University of Texas MD Ander... Our model identified that each unit increase in D25% is significantly associated with a 12% shorter time to ORNJ (Adjusted Time Ratio [ATR] 0·88, p<0·005); pre-RT dental extractions was associated to ... This study is the first to demonstrate a direct relationship between radiation dose and the time to ORNJ onset, providing a novel characterization of the impact of delivered dose not only on the proba... This work was supported by various funding sources including NIH, NIDCR, NCI, NAPT, NASA, BCM, Affirmed Pharma, CRUK, KWF Dutch Cancer Society, NWO ZonMw, and the Apache Corporation....

The World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) Trial: study protocol for a multi-country, multi-centre, double-blind, three-arm, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at high probability of late preterm birth in hospitals in low- resource countries.

Preterm birth complications are the leading cause of newborn and under-5 mortality. Over 85% of all preterm births occur in the late preterm period, i.e. between 34 and < 37 weeks of gestation. Antena... WHO ACTION III trial is a parallel-group, three-arm, individually randomized, double-blind, placebo-controlled trial of two ACS regimens: dexamethasone phosphate 4 × 6 mg q12h or betamethasone phospha... This trial will evaluate the benefits and possible harms of ACS when used in women likely to have a late preterm birth. It will also evaluate a lower-dose ACS regimen based on literature from pharmaco... ISRCTN11434567 . Registered on 7 June 2021....